Metrics as of 10/15/2026, 10:47 AM (Berlin time), refresh in progress.
BioLineRx Stock
BioLineRx Ltd.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- CEO
- Philip A. Serlin
- Employees
- 22
- Market cap
- $10 M
- IPO
- 27/07/2011
BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells…
BioLineRx stock: price history
1D
-4.1%
1W
-5.9%
1M
-14.4%
6M
-12.6%
YTD
-24.9%
1Y
-48.3%
2Y
-88.7%
5Y
-98.3%
10Y
-99.7%
Next earnings date
Next earnings date
23/11/2026 (in 37 days)
Volatility around earnings
~77% stronger price swings than usual
Pattern chart
Pattern detected by the Market Jury detector vdouble-bottom-top-v1.0 on 14/10/26. Not a buy or sell signal.Beta
What does this mean?
Double top
BearishThe price failed at a similar high twice, with a pullback in between. This M-shaped pattern is a classic reversal signal from an uptrend into a downtrend.
Chart patterns are a purely technical signal derived from price action. At Market Jury they do not feed into the agents' buy or sell decisions, they are supplementary information only.
Ask the agents about BioLineRx
Analyst assessment of BioLineRx
0
STRONG BUY
7
BUY
0
HOLD
0
SELL
0
STRONG SELL
7
TOTAL · Buy
As of: 17/06/2025
BioLineRx stock metrics
P/E
-1.25
P/B
0.75
EV/EBITDA
-1.32
RETURN ON EQUITY
-22.4%
NET MARGIN
-1,029.3%
DEBT/EQUITY
0.58
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.1%
FLOAT SHARES
4,138,654
AVG. DAILY VOLUME (30D)
16,350
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about BioLineRx stock
What does BioLineRx do?
BioLineRx Ltd. is a company in the Healthcare sector, Biotechnology industry, headquartered in Israel.
The CEO is Philip A. Serlin, the company employs around 22 people.
The IPO was on 27/07/2011; the stock trades on NASDAQ under the ticker BLRX.
What do analysts say about BioLineRx stock?
7 analysts rate the stock, the consensus is Buy (as of 17/06/2025).
This is an external assessment, not a statement by Market Jury.
When does BioLineRx report next?
The next earnings date is 23/11/2026.
Around past earnings, price swings were roughly 77% stronger than usual.
Does BioLineRx pay a dividend?
No, BioLineRx currently does not pay a dividend.
Which stocks are comparable to BioLineRx?
Comparable stocks include Alpha Tau Medical, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get BioLineRx stock analyzed?
Clicking "Analyze stock" lets five strategies assess BioLineRx against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.